LGALS2 (galectin-2) is a carbohydrate-binding protein that plays diverse roles in immune regulation and disease pathogenesis 1. The protein is predominantly expressed in the gastrointestinal tract but is also found in cardiovascular and placental tissues, where it contributes to epithelial integrity and mucus layer strength 1. In immune contexts, LGALS2 demonstrates complex functional roles depending on disease state. In breast cancer, elevated LGALS2 expression correlates with improved survival outcomes and is associated with tertiary lymphoid structure-associated dendritic cell activation, promoting a 'hot' tumor microenvironment with robust anti-tumor immune responses 23. Conversely, in acute-on-chr22 liver failure, LGALS2 upregulation in classical monocytes is associated with poor recovery outcomes, characterized by inflammatory gene expression and stress responses 4. Genetic polymorphisms in LGALS2, particularly rs7291467, have been linked to coronary artery disease susceptibility and coronary atherosclerosis severity 56. The protein's involvement extends to autoimmune diseases, with polymorphisms potentially affecting rheumatoid arthritis risk 7. These findings suggest LGALS2 functions as a context-dependent immune modulator with both protective and pathogenic potential across different disease states.